glp-1 drugs no insurance Does health cover medications for diabetes and weight loss? Medicaid Coverage of and Spending

National Post reports generic semaglutide products could reach Canadian pharmacy shelves by summer 2026 as Health Canada reviews nine applications.

If a product has not been FDA-approved for a specific condition, it cannot be promoted as safe or effective for that condition

The Global GLP-1 Receptor Agonists Obesity Drugs Market was valued at USD 9.96 Billion in 2024 and is expected to reach USD 33.12 Billion by 2032, growing at a CAGR of 16.20% (2025-2032).

Rationale Obesity remains a major global health challenge, severely affecting metabolic and cardiovascular health

Imitation drugs, unexpected benefits, serious pitfallsheres what comes next as GLP-1 medications continue to rise in popularity

The growing popularity of GLP-1 receptor agonistsincluding Ozempic and Wegovy from Novo Nordisk, and Mounjaro and Zepbound from Eli Lillyhas added fuel to an already fiery debate over the governments